Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neurogene Inc. (NGNE)

Neurogene Q3 2026 net loss widens to $29.0 million from $21.0 million

Negative Impact 3 of 5 earnings

Neurogene Inc. reported third quarter 2026 results, with a net loss of $29.0 million for the three months ended September 30, 2026, up from $21.0 million a year earlier. Higher R&D and G&A spending, driven largely by NGN-401 development and stock-based compensation, drove the increase, and the company said its cash position is expected to fund operations into the first quarter of 2029.

Key points

  • Net loss was $29.0 million for Q3 2026, compared with $21.0 million for Q3 2025.
  • R&D expenses rose to $23.5 million from $17.2 million, mainly for NGN-401 clinical trial and manufacturing activities.
  • G&A expenses rose to $8.9 million from $6.6 million, mainly from higher non-cash stock-based compensation.
  • Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026, expected to fund operations into the first quarter of 2029.

The filing

CompanyNeurogene Inc. (NGNE)
Form8-K, current report
Filed with the SECNov 9, 2026, 8:19 AM ET
Accession number0001404644-26-000064

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:25 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.